|
J Biol Chem, Vol. 273, Issue 41, 26852-26856, October 9, 1998
Activation of Human Endothelial Cells via S-Endo-1 Antigen
(CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion
Kinase p125FAK*
Francine
Anfosso ,
Nathalie
Bardin,
Véronique
Francès,
Eric
Vivier§,
Laurence
Camoin-Jau,
José
Sampol, and
Françoise
Dignat-George
From the Laboratoire d'Hématologie-Immunologie, Unité
de Formation et de Recherche Pharmacie, 13385 Marseille, and the
§ Centre d'Immunologie INSERM-CNRS, Marseille Luminy and
the Institut Universitaire de France, 13288 Marseille,
France
 |
ABSTRACT |
S-Endo-1 antigen (CD146), a transmembrane
receptor also known as MUC18/MCAM, is a member of the immunoglobulin
superfamily and belongs to a group of cell adhesion molecules. CD146 is
highly expressed on the whole vascular tree. We demonstrate here that engagement of CD146 on human endothelial cells isolated from cord blood
results in tyrosine phosphorylation of a large panel of cellular
proteins, although no tyrosine phosphorylation of CD146 was detected.
In particular, CD146 cross-linking induces the tyrosine phosphorylation
of the protein tyrosine kinase p125FAK as well as
p125FAK association with paxillin, both events being
inhibited by cytochalasin D. No direct association of CD146 with
p125FAK was observed. Consistent with these data, CD146
associates with p59fyn, a Src family
kinase known to phosphorylate p125FAK. The identification
of a signaling pathway initiated by CD146 engagement and which includes
p59fyn, p125FAK, and
paxillin indicates that CD146 participates in outside-in signaling in
endothelial cells.
 |
INTRODUCTION |
S-Endo-1 antigen (CD146) is an integral membrane protein present
on human endothelial cells. It is identical to MUC18/MCAM, an antigen
found on melanoma cells. CD146 is ubiquitously present on the
endothelium along the whole vascular tree and is highly expressed on
human umbilical vein endothelial cells
(HUVECs)1 (1, 2). CD146
expression is not restricted to the endothelium; it is also detected in
nonmalignant and malignant cells from other tissues (3-7).
CD146 (113-119 kDa) is a highly glycosylated monomer that belongs to
the immunoglobulin (Ig) superfamily of cell adhesion molecules (1, 8,
9). CD146 contains five extracellular Ig-like homology domains
(V-V-C2-C2-C2), one transmembrane segment, and a short cytoplasmic tail
(10). CD146 molecular cloning has revealed significant homology to
other Ig superfamily adhesion molecules such as B-CAM, ALCAM,
BEN/DM-GRASP/SC1, KG-CAM, the chicken HEMCAM, and gicerin (11-16).
CD146 function is still not elucidated, although recent data suggest
its involvement in cell-cell adhesion. Indeed, the expression of CD146
on melanoma cells correlates with an invasive phenotype, indicating
that CD146 may be used as a cell surface marker of tumor progression
and metastasis formation (17-19). Indeed, CD146 has been shown to be
involved in tumor-endothelial cell interactions that might lead to
extravasation of tumor cells (20, 21). Finally, it has been reported
that CD146 mediates a Ca2+-independent homotypic melanoma
cell adhesion by promoting heterophilic interaction through a still
unknown ligand (19, 21).
CD146 is located at the interendothelial junctions. It is found in
cytoskeletal protein-rich fractions and colocalizes with -actinin
(22).2 It is well documented
that proteins present at the interendothelial junctions promote
adhesion through their extracellular domain and mediate intracellular
signaling to the complex network of cytoskeletal proteins through their
intracytoplasmic part (23). CD146 possesses potential recognition sites
for protein kinases in its cytoplasmic tail (9) which might be involved
in signal transduction. Nevertheless, CD146 involvement in outside-in
signaling in HUVECs has not been investigated.
In this present report, we investigated the signaling pathways
initiated by CD146 engagement. Because the ligand of CD146 is unknown,
CD146 clustering was performed using anti-CD146 monoclonal antibody
(mAb) on HUVECs. Results indicate that cross-linking of CD146 induces
tyrosine phosphorylation of a large panel of proteins, among which
p125FAK and paxillin associate with each other. However,
CD146 is not directly bound to these proteins but becomes associated
with p59fyn. Thus, our results
indicate that CD146 engagement may initiate a reorganization of the
cytoskeleton through a p59fyn- and
p125FAK-dependent pathway.
 |
EXPERIMENTAL PROCEDURES |
Antibodies--
The following mAbs and polyclonal antibodies
were used: S-Endo-1 (F(ab')2 fragment) and 7A4 mAbs, both
specific for CD146 and kindly given by Biocytex (Marseilles, France);
anti-Tyr(P) 4G10 (Upstate Biotechnology, Lake Placid, NY) and PY20
(Transduction Laboratories, Lexington, KY) mAbs;
anti-p125FAK, anti-paxillin,
anti-p53/56lyn,
p59fyn mAbs (Transduction
Laboratories); rabbit anti-p72syk (kindly
given by Dr. R. Geahlen, IN); isotype-matched IgG1 or IgG2a (Sigma, St.
Louis, MO); horseradish peroxidase-labeled goat anti-rabbit, goat
anti-mouse (GAMIg) and its F(ab')2 fragment (Jackson
laboratories, Palo Alto, CA).
Cell Culture--
HUVECs were isolated from cord blood (24).
They were used at confluence after one passage. They were rendered
quiescent by incubation in RPMI 1640 medium containing 1% fetal calf
serum 2 h before cell activation.
Cell Activation and Inhibitor Treatment--
Quiescent HUVECs
were incubated in Hanks' balanced salt solution for 30 min at 4 °C
with either isotype-matched IgG1 (control cells) or 10 µg/ml S-Endo-1
F(ab')2 mAb for CD146 clustering; when indicated, cells
were further stimulated with 20 µg/ml F(ab')2 GAMIg for
30 min at 37 °C. After three washes at 4 °C, the cells were lysed
for immunoblotting.
Genistein, Herbimycin, and Cytochalasin D (Alexis, San Diego, CA) were
used at 50, 10, and 5 µM, respectively. HUVECs were incubated with the drugs in serum-free Hanks' balanced salt solution 1 h before the clustering of CD146 with S-Endo-1 mAb.
Peroxovanadate (NaV) was generated as described previously (25). HUVECs
were incubated in presence of a 100 µM NaV solution for
up to 15 min.
Immunoprecipitation--
After activation, the cells were lysed
at 4 °C in 500 µl of lysis buffer (10 mM Tris-HCl, pH
7.5, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40,
2 mM sodium orthovanadate, 50 mM sodium
fluoride, 1 mM phenylmethylsulfonyl fluoride, 25 µg/ml
aprotinin, 2 µg/ml leupeptin, 2 µg/ml pepstatin). After adjustment
to a protein concentration of 300-500 µg, i.e. 3-6 × 106 cells (bicinchoninic acid assay, Pierce, Rockford,
IL), cell lysates were precleared by incubation with irrelevant IgG1 or IgG2a mAbs and protein G-Sepharose (Pharmacia Biotech, Uppsala, Sweden)
for 1 h at 4 °C. Precleared samples were immunoprecipitated with 2 µg for 3 h at 4 °C followed by a 2-h incubation with
protein G-Sepharose. Immunoprecipitates were analyzed by SDS-PAGE and immunoblotting. Immunoprecipitations using anti-CD146 and anti-Tyr(P) were performed, respectively, with S-Endo-1 and 4G10 mAbs.
Immunoblotting--
Immunoprecipitates or total cell lysates
were subjected to SDS-PAGE and transferred to nitrocellulose
C+ filters. After blocking in 10 mM Tris-HCl
buffer, pH 7.5, 0.15 M NaCl, 0.1% Tween 20, 3% bovine
serum albumin (TBS-T BSA), they were incubated in TBS-T BSA containing
protein-specific antibodies (1 µg/ml) for 1 h at room
temperature. Immunoreactive bands were visualized by chemiluminescence
using horseradish peroxidase-conjugated anti-mouse or rabbit IgG and
ECL reagent. Western blotting using anti-CD146 was performed with 7A4
mAb. When required, membranes were stripped in 62.5 mM
Tris-HCl, pH 6.8, 2 mM EDTA, 2% SDS, 100 mM
-mercaptoethanol for 30 min at 60 °C and reblotted with the
indicated antibodies.
 |
RESULTS |
CD146 Engagement Induces a Pattern of Tyrosine-phosphorylated
Proteins in HUVECs--
Engagement of CD146 was obtained by incubating
HUVECs with S-Endo-1 F(ab')2 mAb and subsequently by
cross-linking the complexes with GAMIg. Whole cell lysates were
analyzed on a 5-15% gradient SDS-PAGE followed by immunoblotting with
anti-Tyr(P) mAb. In HUVECs, engagement of CD146 induced the tyrosine
phosphorylation of a large panel of proteins (Fig.
1, lane 2), which was
increased further upon cross-linking with GAMIg at 37 °C for 30 min
(Fig. 1, lane 3). The complex pattern of
tyrosine-phosphorylated proteins consistently includes proteins at
apparent molecular masses of 46, 55-60, 70-80, 100, 125, and 150 kDa.
A 2-h pretreatment of HUVEC with 50 µM genistein (Fig. 1,
lane 4) or 2 µM herbimycin (Fig. 1, lane
5) greatly reduced the tyrosine phosphorylation induced by CD146
engagement. Kinetic analysis of the induction of tyrosine
phosphorylation upon CD146 engagement revealed a rapid onset after 5 min, a maximum at 30 min, followed by a decrease thereafter (data not
shown). In contrast, in HUVECs treated with a control isotype-matched
(IgG1) antibody cross-linked with GAMIg, a pattern of constitutive
tyrosine phosphorylation was barely detectable (Fig. 1, lane
1).

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 1.
Induction of tyrosine phosphorylation by
CD146 engagement in HUVECs. HUVECs were treated by S-Endo-1
(F(ab')2) mAb fragment alone or cross-linked with GAMIg as
described under "Experimental Procedures." Genistein (50 µM) or herbimycin (2 µM) was added 2 h
before cell activation. After cell lysing, 50 µg of proteins was
analyzed on a linear 5-15% gradient SDS-PAGE. Immunoblotting was
performed with PY20 anti-Tyr(P). The position of prestained standards
and their molecular masses in kDa are indicated. C indicates
IgG1 isotype-matched control cells. Results are representative of five
independent experiments.
|
|
CD146 Clustering Did Not Induce CD146 Phosphorylation--
The
presence of a tyrosine residue at position 641 (Tyr-Ile-Asp-Leu) in
CD146 cytoplasmic tail suggests a potential site of phosphorylation of
the molecule (9). The capacity of CD146 engagement to phosphorylate
Tyr641 was studied. As shown in Fig.
2 (upper panel), anti-Tyr(P)
immunoblotting of anti-CD146 immunoprecipitation revealed that CD146 is
not tyrosine-phosphorylated, either in isotype-matched control
(lane 1) or in CD146-stimulated cells (lane 2).
Reciprocal experiments, using anti-CD146 immunoblotting of anti-Tyr(P)
immunoprecipitation, led to similar results (Fig. 2, upper panel,
lane 4). As a control, immunoprecipitation and immunoblotting with
anti-CD146 mAbs revealed the presence of CD146 in these samples (Fig.
2, lower panel).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
CD146 is not a tyrosine-phosphorylated
protein. HUVECs were either activated by CD146 engagement or
incubated with 0.1 mM NaV, as described under
"Experimental Procedures." Lysates (300 µg) were
immunoprecipitated (IP) using S-Endo-1 or 4G10 mAbs,
separated on 7% SDS-PAGE, and immunoblotted (WB) using 7A4
or PY20 mAbs as indicated (upper panel). Blots were then
stripped and reblotted with 7A4 mAb (lower panel).
C indicates IgG1 isotype-matched control cells.
|
|
NaV is a potent inducer of tyrosine phosphorylation (25) and was tested
for its ability to promote tyrosine phosphorylation of CD146. HUVECs
were treated with 0.1 mM NaV for 15 min and lysed. No
tyrosine phosphorylation in the molecular weight range of CD146 was
observed in anti-Tyr(P) immunoblots of anti-CD146 immunoprecipitates (Fig. 2, lane 3), although CD146 was present in the cell
lysate after reblotting. The lack of tyrosine phosphorylation in CD146 was observed irrespective of the dose of NaV (0.2-3 mM)
and time of incubation (2-30 min) used in the experiments (data not
shown).
CD146 Engagement Induces Tyrosine Phosphorylation of
p125FAK and Paxillin--
The colocalization of CD146 with
cytoskeletal proteins2 and the tyrosine phosphorylation of
a band in the molecular weight range of 125,000 suggested that
p125FAK could be tyrosine-phosphorylated upon CD146
engagement (26). To examine whether CD146 engagement stimulates
tyrosine phosphorylation of p125FAK in HUVECs, cell lysates
were immunoprecipitated with anti-p125FAK mAb and
immunoblotted with anti-Tyr(P) mAb. Fig.
3A shows that a constitutive
tyrosine phosphorylation of p125FAK occurs in
isotype-matched control cells (lane 1). CD146 engagement caused a marked increase in the tyrosine phosphorylation of
p125FAK (Fig. 3A, lane 2). Disruption
of the actin network by a 2-h pretreatment of the HUVEC monolayer with
5 µM cytochalasin D inhibited the p125FAK
tyrosine phosphorylation mediated by CD146 clustering (Fig.
3A, lane 3).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 3.
CD146 engagement stimulates
p125FAK tyrosine phosphorylation and paxillin association
to p125FAK in HUVECs. CD146 engagement was performed
as described under "Experimental Procedures." Lysates (300 µg)
were immunoprecipitated, separated on 7% SDS-PAGE, and immunoblotted
as indicated. C indicates IgG1 isotype-matched control
cells. Panel A, tyrosine phosphorylation of
p125FAK induced by CD146 engagement in absence or after
pretreatment with 5 µM cytochalasin D. Panel
B, lack of association of p125FAK with CD146.
Lysates were immunoprecipitated using S-Endo-1 and immunoblotted with
anti-FAK mAbs (upper panel). Blots were then stripped and
reblotted with 7A4 mAb (lower panel). Panel
C, tyrosine phosphorylation of paxillin and its
association with p125FAK.
|
|
A direct association between CD146 and p125FAK was
investigated in response to CD146 engagement. Cell lysates were
immunoprecipitated with anti-CD146 and immunoblotted with
anti-p125FAK. No protein in the molecular mass range of
125 kDa was detected (Fig. 3B, upper panel), although
reprobing with anti-CD146 mAb indicated that CD146 was present in
anti-CD146 immunoprecipitates (Fig. 3B, lower panel). These
results showed that CD146 cross-linking induces p125FAK
phosphorylation but does not induce an association between CD146 and
p125FAK.
Tyrosine phosphorylation of paxillin, a substrate for
p125FAK (27), and its association with p125FAK
were investigated in response to CD146 engagement. Results in Fig.
3C indicate that CD146 cross-linking induces tyrosine
phosphorylation of a protein in the range of 70 kDa detected by
anti-paxillin mAb after immunoprecipitation with anti-Tyr(P)
(lane 1). Association of paxillin with p125FAK
was then examined. Detection of paxillin in anti-p125FAK
immunoprecipitates was observed after CD146 engagement (Fig. 3C, lane 3) and was not revealed in lysates from
cells stimulated with isotype-matched control mAb (Fig. 3C,
lane 2). A 2-h treatment of HUVECs with 5 µM
cytochalasin D before CD146 cross-linking inhibits paxillin association
with p125FAK entirely (Fig. 3C, lane
4).
CD 146 Clustering Results in the Association of
p59fyn with
CD146--
Because CD146 engagement induces the tyrosine
phosphorylation of p125FAK and paxillin, we investigated
whether CD146 engagement results in the recruitment of PTK(s) in the
vicinity of CD146. In this regard, p125FAK possesses
several binding sites for Src or Src-related kinases (26). In addition,
CD146 engagement induces tyrosine phosphorylation of proteins with
molecular masses ( 55-80 kDa) close to those of Src-related kinases
such as p53/56lyn and
p59fyn, as well as other PTKs such
as p72syk, all known to bind
p125FAK. We next determine whether these PTKs are involved
in CD146 signal pathway. No association between
p53/56lyn or
p72syk with
CD146 was detected (Fig. 4, upper panel), although
reprobing with anti-CD146 mAb confirmed the presence of CD146 in
anti-CD146 immunoprecipitates (Fig. 4, lower panel). These
results indicated that CD146 cross-linking induces the recruitment of
p59fyn kinase to CD146.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 4.
Association of CD146 with
p59fyn. CD146 engagement was
performed as described under "Experimental Procedures." Lysates
(500 µg) were immunoprecipitated using S-Endo-1 mAb.
Immunoprecipitates were first immunoblotted with the indicated anti-PTK
antibodies (upper panel) and reblotted with 7A4 mAb
(lower panel).
|
|
 |
DISCUSSION |
The results reported here demonstrate that in cultured HUVECs,
engagement of CD146 initiates a PTK-dependent signaling
cascade. Activation of this pathway results in the tyrosine
phosphorylation of a complex pattern of proteins, including
p125FAK and paxillin as well as the association of
p59fyn with CD146. To our knowledge,
this is the first report demonstrating an outside-in signaling pathway
downstream of CD146.
Dimerization of cell surface receptors represents a key event in signal
transduction (28). Binding of S-Endo-1 mAb to the extracellular part of
CD146 induces a dimerization of CD146 sufficient to promote the
tyrosine phosphorylation of intracellular proteins. Cross-linking of
CD146 dimers by a secondary antibody leads to an oligomerization of
CD146 which subsequently increases the intensity of the phosphorylation
events. This process is time- and dose-dependent and
requires genistein- and herbimycin-sensitive kinases.
Phosphorylation of tyrosine residues plays an important role in signal
transduction by creating docking sites for SH2 domains of signaling
molecules (29). Although the CD146 molecule contains a tyrosine residue
(Tyr641) in its cytoplasmic tail (10), we cannot detect any
tyrosine phosphorylation of CD146 upon anti-CD146 mAb or upon NaV
treatment. These results indicate that CD146 does not serve as a
docking site for an SH2 adaptor/effector signaling molecule.
We also show here that upon aggregation, CD146 associates with
p59fyn, a nonreceptor PTK belonging
to the Src family kinases (30). p59Fyn possesses adjacent
Src homology SH2 and SH3 domains involved in the binding to target
proteins (31). The lack of tyrosine-phosphorylable CD146 excludes the
binding by the SH2 domain of p59fyn
(32). In an other way, it is known that the SH3 domains bind to a
proline-rich sequence. Although the CD146 cytoplasmic tail contains
proline residues, no consensus sequence for SH3 binding site is found
(33). Therefore, the molecular basis of the
p59fyn interaction with CD146 is
still unknown.
Consistent with the recruitment of p59Fyn to the membrane
upon CD146 engagement, we observe the tyrosine phosphorylation of two major proteins involved in the formation of focal adhesion plaques, p125FAK and paxillin. These results indicate that CD146
cross-linking induces downstream events that activate
p125FAK and mediate its association with its substrates
such as paxillin. Both p125FAK tyrosine phosphorylation and
its association with paxillin depend on the integrity of the
cytoskeleton as they are inhibited by pretreatment of cytochalasin D
(34).
It is well known that p125FAK possesses high affinity
binding sites for members of Src family kinases, including
p59fyn, which in turn can
phosphorylate other tyrosines on p125FAK (26).
p59fyn participates in the
phosphorylation of Tyr at positions 397, 576, 577, and 925, present in
the catalytic and COOH-terminal domains of p125FAK (27, 35,
36). These phosphorylations create multiple binding sites for substrate
proteins (26, 38) including paxillin, tensin, and p130Cas
(39-41). Paxillin is a cytoskeletal protein that localizes to sites of
adhesion and binds to two sequences present in the carboxyl terminus of
p125FAK (42, 43). Its association with p125FAK
is thought to modulate the localization of p125FAK to focal
adhesion plaques (44-46). Taken together, the results suggest that
CD146 engagement mediates the formation of a complex among CD146,
p59fyn, p125FAK, and
paxillin, which promotes focal adhesion assembly.
It is tempting to speculate that CD146 engagement does not only involve
an outside-in PTK pathway in HUVEC but also initiates an inside-out
PTK-dependent signaling pathway. In mice,
p125FAK gene inactivation impairs cell motility (47),
whereas its overexpression stimulates cell migration (48). In addition,
p125FAK and paxillin phosphorylations are increased by cell
density (37). Preliminary results2 indicate that CD146
expression on the plasma membrane is also increased by cell density.
CD146 might therefore participate in the establishment of the
endothelial monolayer by initiating downstream events that promote cell
proliferation and monolayer formation.
Taken together, the data presented here indicate a role of CD146 in
signaling. They suggest that interaction of CD146 with its still
unknown ligand might lead to a similar signaling pathway.
 |
ACKNOWLEDGEMENTS |
We thank Anny Bottary, Andrée Boyer and
Patricia Stellmann for skillful technical assistance and
Corinne Beziers La Fosse (CIML, Marseille, France) for assistance in
preparing figures. We are grateful to the Biocytex company for
providing 7A4 mAb and S-Endo-1 F(ab')2 fragment.
 |
FOOTNOTES |
*
This work was supported by Grant UPRES EA 2195 from the
Ministère de l'Education Nationale.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Laboratoire
d'Hématologie-Immunologie, UFR Pharmacie 27, Bd Jean Moulin,
13385 Marseille cedex 5, France. Tel.: 33-4-9183-5600; Fax:
33-4-9183-5602; E-mail: hematim{at}pharmacie.univ-mrs.fr.
The abbreviations used are:
HUVEC, human
umbilical vein endothelial cell; mAb, monoclonal antibody; Tyr(P), phosphotyrosine; anti-Tyr(P) mAb, mouse monoclonal antibody against
phosphotyrosine; GAMIg, goat anti-mouse immunoglobulin; NaV, peroxovanadate; PAGE, polyacrylamide gel electrophoresis; PTK, protein
tyrosine kinase; C, constant; V, variable.
2
N. Bardin, V. Francès, J. Sampol, and F. Dignat-George, manuscript in preparation.
 |
REFERENCES |
-
Bardin, N.,
George, F.,
Mutin, M.,
Brisson, C.,
Horschowski, N.,
Francès, V.,
Lesaule, G.,
and Sampol, J.
(1996)
Tissue Antigens
48,
531-539[Medline]
[Order article via Infotrieve]
-
Bardin, N.,
Francès, V.,
Lesaule, G.,
Horschowski, N.,
George, F.,
and Sampol, J.
(1996)
Biochem. Biophys. Res. Commun.
218,
210-216[CrossRef][Medline]
[Order article via Infotrieve]
-
Shih, I. M.,
Elder, D. E.,
Speicher, D.,
Johnson, J. P.,
and Herlyn, M.
(1994)
Cancer Res.
54,
2514-2520[Abstract/Free Full Text]
-
Shih, I. M.,
and Kurman, R.
(1996)
Lab. Invest.
75,
377-388[Medline]
[Order article via Infotrieve]
-
Pickl, W. F.,
Majdic, O.,
Fischer, G. F.,
Petzelbauer, P.,
Faé, L.,
Waclavicek, M.,
Stöckl, J.,
Scheinecker, C.,
Vidicki, T.,
Aschauer, H.,
Johnson, J. P.,
and Knapp, W.
(1997)
J. Immunol.
158,
2107-2115[Abstract]
-
Shih, I. E.,
Hsu, M. Y.,
Palazzo, J. P.,
and Herlyn, M.
(1997)
Am. J. Pathol.
151,
745-751[Abstract]
-
Shih, I. M.,
Wang, T. L.,
and Westra, W. H.
(1996)
Clin. Cancer Res.
2,
569-575[Abstract]
-
Lehmann, J. M.,
Holzmann, B.,
Breitbart, E. W.,
Schmiegelow, P.,
and Johnson, J. P.
(1987)
Cancer Res.
47,
841-845[Abstract/Free Full Text]
-
Sers, C.,
Kirsch, K.,
Rothbächer, U.,
Riethmüller, G.,
and Johnson, J. P.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8514-8518[Abstract/Free Full Text]
-
Lehmann, J. M.,
Riethmüller, G.,
and Johnson, J. P.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
9891-9895[Abstract/Free Full Text]
-
Taira, E.,
Takaha, N.,
Taniura, H.,
Kim, C. H.,
and Miki, N.
(1994)
Neuron
12,
861-872[CrossRef][Medline]
[Order article via Infotrieve]
-
Campbell, I. G.,
Foulkes, W. D.,
Senger, G.,
Trowsdale, J.,
Garin-Chesa, P.,
and Rettig, W. J.
(1994)
Cancer Res.
54,
5761-5765[Abstract/Free Full Text]
-
Bowen, M.,
Patel, D. D.,
Li, X.,
Modrell, B.,
Malacko, A. R.,
Wang, W. C.,
Marquardt, H.,
Neubauer, M.,
Pesando, J. M.,
and Francke, U.
(1995)
J. Exp. Med.
181,
2213-2220[Abstract/Free Full Text]
-
Laessing, U.,
Giordano, S.,
Stecher, B.,
Lottspeich, F.,
and Stuemer, C. A. O.
(1996)
Differentiation
56,
21-29[CrossRef]
-
Peduzzi, J. D.,
Irwin, M. H.,
and Giesert, E. E.
(1994)
Brain Res.
640,
296-307[CrossRef][Medline]
[Order article via Infotrieve]
-
Vaino, O.,
Dunon, D. L.,
Aissi, F.,
Dangy, J. P.,
McNagny, K. M.,
and Imhof, B. A.
(1996)
J. Cell Biol.
135,
1655-1668[Abstract/Free Full Text]
-
Luca, M.,
Hunt, B.,
Bucana, C. D.,
Johnson, J. P.,
Fidler, I. J.,
and Bar-Eli, M.
(1993)
Melanoma Res.
3,
35-41[Medline]
[Order article via Infotrieve]
-
Sers, C.,
Riethmüller, G.,
and Johnson, J. P.
(1994)
Cancer Res.
54,
5689-5694[Abstract/Free Full Text]
-
Xie, S.,
Luca, M.,
Huang, S.,
Gutman, M.,
Reich, R.,
and Johnson, J.
(1997)
Cancer Res.
57,
2295-2303[Abstract/Free Full Text]
-
Johnson, J. P.,
Bar-Eli, M.,
Jansen, B.,
and Markhof, E.
(1997)
Int. J. Cancer
73,
769-774[CrossRef][Medline]
[Order article via Infotrieve]
-
Shih, I. E.,
Speicher, D.,
Hsu, D.,
Levine, E.,
and Herlyn, M.
(1997)
Cancer Res.
57,
3835-3840[Abstract/Free Full Text]
-
Ming, I. E.,
Elder, D. E.,
Speicher, D.,
Johnson, J. P.,
and Herlyn, M.
(1994)
Cancer Res.
54,
2514-2520
-
Lampugnani, M. G.,
and Dejana, E.
(1997)
Curr. Opin. Cell Biol.
9,
674-682[CrossRef][Medline]
[Order article via Infotrieve]
-
Jaffe, E.,
Nachman, R.,
Becker, C.,
and Minick, C.
(1973)
J. Clin. Invest.
52,
2745-2756
-
Donnadieu, E.,
Trautmann, A.,
Malissen, M.,
Trucy, J.,
Malissen, B.,
and Vivier, E.
(1994)
J. Biol. Chem.
269,
32828-32834[Abstract/Free Full Text]
-
Schaller, M. D.,
Borgman, C. A.,
Cobb, B. S.,
Vines, R. R.,
Reynolds, A. B.,
and Parsons, J. T.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5192-5196[Abstract/Free Full Text]
-
Calalb, M. B.,
Polte, T. R.,
and Hanks, S. K.
(1995)
Mol. Cell. Biol.
15,
954-963[Abstract]
-
Schlessinger, J.
(1997)
Cell
91,
869-872[CrossRef][Medline]
[Order article via Infotrieve]
-
Koch, C. A.,
Anderson, D.,
Moran, M. F.,
Ellis, C.,
and Pawson, T.
(1991)
Science
252,
668-674[Abstract/Free Full Text]
-
Kypta, R. M.,
Hemming, A.,
and Courtneidge, S. A.
(1988)
EMBO J.
7,
3837-3844[Medline]
[Order article via Infotrieve]
-
Panchamoorthy, G.,
Fukazawa, T.,
Stolz, L.,
Payne, G.,
Reedquist, K.,
Shoelson, S.,
Zhou, S.,
Cantley, L.,
Walsh, C.,
and Band, H.
(1994)
Mol. Cell. Biol.
14,
6372-6385[Abstract/Free Full Text]
-
Small, S. J.,
Shull, G. E.,
Santioni, M. J.,
and Akeson, R.
(1987)
J. Cell Biol.
105,
2335-2345[Abstract/Free Full Text]
-
Pawson, T.,
and Scott, J. D.
(1997)
Science
278,
2075-2080[Abstract/Free Full Text]
-
Seufferlein, T.,
and Rozengurt, E.
(1994)
J. Biol. Chem.
269,
9345-9351[Abstract/Free Full Text]
-
Schaller, M. D.,
Hildebrand, J. D.,
Shannon, J. D.,
Fox, J. W.,
Vines, R. R.,
and Parsons, J. T.
(1994)
Mol. Cell. Biol.
14,
1680-1688[Abstract/Free Full Text]
-
Calalb, M. B.,
Zhang, X.,
Polte, T. R.,
and Hanks, S. K.
(1996)
Biochem. Biophys. Res. Commun.
228,
662-668[CrossRef][Medline]
[Order article via Infotrieve]
-
Batt, D. B.,
and Roberts, T. M.
(1998)
J. Biol. Chem.
273,
3408-3414[Abstract/Free Full Text] s
-
Schaller, M. D.
(1996)
J. Endocrinol.
150,
1-7[Abstract/Free Full Text]
-
Turner, C. E.,
Glenney, J. R.,
and Burridge, K.
(1990)
J. Cell Biol.
111,
1059-1068[Abstract/Free Full Text]
-
Lo, S. H.,
Weisberg, E.,
and Chen, L. B.
(1994)
Bioessays
16,
817-823[CrossRef][Medline]
[Order article via Infotrieve]
-
Petch, L. A.,
Bockholt, S. M.,
Bouton, A.,
Parsons, J. T.,
and Burridge, K.
(1995)
J. Cell Sci.
108,
1371-1379[Abstract]
-
Hildebrand, J. D.,
Schaller, M. D.,
and Parsons, J. T.
(1995)
Mol. Biol. Cell
6,
637-647[Abstract]
-
Brown, M. C.,
Perrotta, J. A.,
and Turner, C. E.
(1996)
J. Cell Biol.
135,
1109-1123[Abstract/Free Full Text]
-
Turner, C. E.,
Schaller, M. D.,
and Parsons, J. T.
(1993)
J. Cell Sci.
105,
637-645[Abstract]
-
Bellis, S. L.,
Miller, J. T.,
and Turner, C. E.
(1995)
J. Biol. Chem.
270,
17437-17441[Abstract/Free Full Text]
-
Tachibana, K.,
Sato, T.,
D'Aviro, N.,
and Morimoto, C.
(1995)
J. Exp. Med.
182,
1089-1099[Abstract/Free Full Text]
-
Illic, D.,
Furuta, Y.,
Kanazawa, S.,
Takeda, N.,
Sobue, K.,
Nakatsuji, N.,
Nomura, S.,
Fujimoto, J.,
Okada, M.,
Yamamoto, T.,
and Alzawa, S.
(1995)
Nature
377,
539-544[CrossRef][Medline]
[Order article via Infotrieve]
-
Cary, L. A.,
Chang, J. F.,
and Guan, J. L.
(1996)
J. Cell Sci.
109,
1787-1794[Abstract]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Bardin, M. Blot-Chabaud, N. Despoix, A. Kebir, K. Harhouri, J.-P. Arsanto, L. Espinosa, P. Perrin, S. Robert, F. Vely, et al.
CD146 and its Soluble Form Regulate Monocyte Transendothelial Migration
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2009;
29(5):
746 - 753.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Guezguez, P. Vigneron, N. Lamerant, C. Kieda, T. Jaffredo, and D. Dunon
Dual Role of Melanoma Cell Adhesion Molecule (MCAM)/CD146 in Lymphocyte Endothelium Interaction: MCAM/CD146 Promotes Rolling via Microvilli Induction in Lymphocyte and Is an Endothelial Adhesion Receptor
J. Immunol.,
November 15, 2007;
179(10):
6673 - 6685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bu, L. Gao, J. Zhuang, J. Feng, D. Yang, and X. Yan
Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-{kappa}B activation.
Mol. Cancer Ther.,
November 1, 2006;
5(11):
2872 - 2878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cerletti, M. J. Molloy, K. K. Tomczak, S. Yoon, M. F. Ramoni, A. T. Kho, A. H. Beggs, and E. Gussoni
Melanoma cell adhesion molecule is a novel marker for human fetal myogenic cells and affects myoblast fusion
J. Cell Sci.,
August 1, 2006;
119(15):
3117 - 3127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Schulz, V. Petrig, K. Wolf, K. Kratzel, M. Kohler, B. Becker, and M. Pfeifer
Upregulation of MCAM in primary bronchial epithelial cells from patients with COPD
Eur. Respir. J.,
September 1, 2003;
22(3):
450 - 456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Yan, Y. Lin, D. Yang, Y. Shen, M. Yuan, Z. Zhang, P. Li, H. Xia, L. Li, D. Luo, et al.
A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth
Blood,
July 1, 2003;
102(1):
184 - 191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yoshioka, H. Fujiwara, T. Higuchi, S. Yamada, M. Maeda, and S. Fujii
Melanoma cell adhesion molecule (MCAM/CD146) is expressed on human luteinizing granulosa cells: enhancement of its expression by hCG, interleukin-1 and tumour necrosis factor-{alpha}
Mol. Hum. Reprod.,
June 1, 2003;
9(6):
311 - 319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Bardin, F. Anfosso, J.-M. Masse, E. Cramer, F. Sabatier, A. L. Bivic, J. Sampol, and F. Dignat-George
Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion
Blood,
December 15, 2001;
98(13):
3677 - 3684.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Alais, N Allioli, C Pujades, J. Duband, O Vainio, B. Imhof, and D Dunon
HEMCAM/CD146 downregulates cell surface expression of (&bgr;)1 integrins
J. Cell Sci.,
January 5, 2001;
114(10):
1847 - 1859.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Anfosso, N. Bardin, E. Vivier, F. Sabatier, J. Sampol, and F. Dignat-George
Outside-in Signaling Pathway Linked to CD146 Engagement in Human Endothelial Cells
J. Biol. Chem.,
January 5, 2001;
276(2):
1564 - 1569.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|